How many investments has Invivo Capital Partners made?

Invivo Capital Partners has 27 tracked investments.

What stage does Invivo Capital Partners invest at?

Invivo Capital Partners invests at the Pre-Seed, Seed, Series A stages.

What is Invivo Capital Partners's typical check size?

Invivo Capital Partners typically writes checks of $2.2M – $4.3M.

What sectors does Invivo Capital Partners focus on?

Invivo Capital Partners focuses on AI & Machine Learning, Biotech, Deep Tech, Healthtech, Medical Devices.

Where is Invivo Capital Partners located?

Invivo Capital Partners is headquartered in Barcelona, ES.

Who does Invivo Capital Partners co-invest with?

Invivo Capital Partners most often shares deals with AdBio partners, Criteria Bio Ventures, Kurma Partners, among 27 tracked co-investors.

Invivo Capital Partners

Venture capital

Barcelona · Pre-Seed–Series A · 11 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Invivo Partners backs early-stage science-driven companies, concentrating on biotechnology firms developing innovative drugs, especially advanced therapies and synthetic biology, as well as ventures spanning AI and deeptech. It invests at pre-seed (company creation), seed (preclinical stage), and directly at Series A for companies 1-2 years from First-in-Human trials. The firm targets European businesses with a special focus on Spanish opportunities, deploying initial checks of 2-4M€ and follow-ons up to 10M€ per company after milestones. Backed by institutional investors including the European Investment Fund, ICO, ICF, IVF, and Barcelona City Council, the team combines scientific, technical, and financial expertise to build a leading position in Europe's biotech industry.

Invests inAI & Machine Learning Biotech Deep Tech Healthtech Medical Devices Barcelona Belgium Europe France Spain Switzerland

Source: firm website, verified Aug 7, 2026.

Stage

Pre-Seed–Series A

Check

$2.2M – $4.3M

Barcelona, ES

Instruments

Equity

Founded

2012

AUM

$165M

Tracked investments

Team · 11 people

from the firm's website & public directories

Timothy Lu· Co-Founder & CEO, Senti Bio

Synthetic biology and biopharmaceutical leader, co-founder and CEO of Senti Bio since 2016, and former MIT faculty member. He holds an M.D. from Harvard and a Ph.D. from MIT and has co-founded multiple biotech companies.

Albert Ferrer· Managing Partner· Greater Barcelona Metropolitan Areain

One of the managers of Invivo Partners.

a•••@invivo.partnersreveal

Laura Rodríguez· Managing Partner· Barcelona, Catalonia, Spainin

One of the managers of Invivo Partners.

l•••@invivo.partnersreveal

Luis Pareras· Managing Partner· Greater Barcelona Metropolitan Areain

One of the managers of Invivo Partners.

l•••@invivo.partnersreveal

Josep M. Martorell· Partner· Barcelona

Physicist and PhD in computer science joining Invivo as Partner. Previously Associate Director at the Barcelona Supercomputing Center, where he led innovation strategy and the AI Factory initiative, and formerly Director General for Research at the Catalan Government. A long-standing angel investor in deeptech.

Gemma Guinart· Principal· Barcelona, Catalonia, Spainin

Gemma Guinart is a Principal at Invivo Partners, a venture capital fund investing in early-stage companies and technology transfer opportunities in drug development. She previously worked as a Project Manager at UPF Ventures. Guinart holds a BSc in Biomedical Sciences from the University of Barcelona, an MSc in Business Management applied to Biotechnology from the Biotechnology Business Institute, and a postgraduate qualification in Financial Management from UPF Barcelona School of Management.

g•••@invivo.partnersreveal

Begoña Carreño· Chief Business Development Officer at Aspeya· Switzerland

Chief Business Development Officer at Aspeya (formerly Vectura Fertin Pharma) with over 20 years of pharmaceutical development experience, including 18 years in Business Development & Licensing at Novartis. She holds a Ph.D. in Drug Delivery and serves on boards including ProQR and the IRB Barcelona advisory board.

Luis Serrano· Director, CRG (Centre for Genomic Regulation)· Spain

Director of the Centre for Genomic Regulation with a Ph.D. in Cell Biology; a recognized leader in Systems and Synthetic Biology, member of EMBO and RACEFyN, and co-founder of six startups. Previously a Group Leader and program head at EMBL.

Theresa Heggie· Biopharmaceutical Executive & Board Member

Accomplished biotech and pharmaceutical executive who joined Freeline as CEO in 2020, with prior senior roles at Alnylam, Bupa, Shire, Baxter, and Janssen. She serves on the boards of BioCryst and ProQR Therapeutics and holds a BSc from Cornell University.

Borja Ruiz· Investment Analyst· Barcelona, Catalonia, Spainin

b•••@invivo.partnersreveal

Cinta Diez· Investment Analyst· Barcelona, Catalonia, Spainin

c•••@invivo.partnersreveal

What they invest in

from 15 of 27 portfolio companies

Biotech ×11Healthtech ×9Medical Devices ×3Deep Tech ×2Fintech ×2GovTech ×2Impact & Social Good ×2AI & Machine Learning ×1

HQs:Spain×5

Investments · 27 tracked

founders shown can be your intro path

Alnylam PharmaceuticalsNASDAQ: ALNY

Biotech firm specializing in RNA interference (RNAi) therapeutics

BioCryst PharmaceuticalsNASDAQ: BCRX

Biotech company developing biopharmaceuticals

Araara.cat in 𝕏

ARA is a Catalan-language news publication offering coverage of international, national, and cultural affairs, along with opinion and special editorial initiatives.

Media & Entertainment

ARTHEx Biotech’s websitearthexbiotech.com in 𝕏

Arthex Biotech develops an investigational anti-miR therapeutic targeting an upregulated miRNA for the treatment of myotonic dystrophy, aiming to address the root cause of the disease.

BiotechMedical Devices

Co-investorsAdBio partners Columbus Venture Partners Sound Bioventures

Baltic Innovation Fund 3eif.org in 𝕏

The European Investment Fund (EIF) provides debt and equity financing to European SMEs and infrastructure projects across their development stages, channelling funding through funds and intermediaries.

FintechImpact & Social Good

Co-investorsAlpine Space Ventures BOM Crowberry Capital Khanu M80 Partners Tesi (Finnish Industry Investment Ltd)+2 more

Barcelonabarcelona.cat

Official municipal website of the city of Barcelona, providing residents with access to public services, administrative procedures, cultural agenda, and city information.

GovTechBarcelona, ES

Corteriapharmacorteriapharma.com in

Corteria Pharmaceuticals develops first-in-class drugs for conditions with high unmet medical need, including worsening and acute decompensated heart failure, right heart failure, sarcopenia, and obesity with complications.

BiotechHealthtech

Co-investorsFountain Healthcare Partners Jeito Capital Kurma Partners LifeArc Ventures OrbiMed V-Bio Ventures

Eclovatxeclovatx.com

A stealth-stage company developing targeted therapeutics.

Biotech

Esobiotecesobiotec.com

Freeline

Gvagva.es

Co-investorsDraper B1

Gyalatxgyalatx.com in

Gyala Therapeutics is a biotech company developing GYA01, an investigational CAR-T cell therapy for hematologic cancers including acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL).

BiotechDeep TechHealthtechBarcelona, ES

Icficf.cat

Icoico.es 𝕏

Instituto de Crédito Oficial (ICO) is Spain's state-owned finance institution providing loans and guarantee lines to self-employed workers, SMEs, and companies, including financing for exports, internationalization, and sustainable projects.

FintechGovTechImpact & Social Good

Integra Therapeuticsintegra-tx.com

Co-investorsAdBio partners Columbus Venture Partners

Minoryx Therapeuticsminoryx.com in

Minoryx is a biopharmaceutical company that discovers and develops drug treatments for severe orphan diseases of the central nervous system, such as cerebral adrenoleukodystrophy and Rett syndrome.

BiotechHealthtech

Co-investorsChiesi Ventures Criteria Bio Ventures Fund+Kurma Partners Roche Venture Fund Ysios Capital +1 more

Neumirna Therapeuticsneumirna.com

Co-investorsIaso Ventures Sunstone Capital

Onechaintxonechaintx.com in 𝕏

OneChain Immunotherapeutics is a clinical-stage biotech developing CAR-T cell therapy candidates as treatments for oncological diseases.

BiotechHealthtech

Pablo Menéndez(Scientific Founder)

Peptomycpeptomyc.com in 𝕏

Peptomyc is a biotech company developing MYC inhibitors for cancer treatment, based on the Omomyc molecule, and is advancing them through preclinical and clinical trials.

BiotechDeep TechHealthtechMedical DevicesBarcelona, ES

Dr. Laura Soucek(Co-founder and CEO)Dr. Marie-Eve Beaulieu(Co-founder)Laura Soucek(Co-founder & CSO (former CEO))

Co-investorsAurora Science Asabys Partners

ProQRproqr.com in 𝕏

ProQR Therapeutics develops RNA editing therapies for patients with genetic disorders through its proprietary Axiomer RNA editing platform.

BiotechHealthtech

Co-investorsPontifax Venture Capital Sofinnova Partners

Pulmobiopulmobio.com

Sanifitsanifit.com in 𝕏

CSL is a biotechnology company that develops and manufactures plasma-derived and other therapies, including biotherapies for rare and serious diseases, vaccines, and treatments for iron deficiency and kidney disease.

BiotechHealthtechMedical Devices

Joan Perello Bestard(Founder)inCris Calsadain

Co-investorsAndera Partners Criteria Bio Ventures Ysios Capital

Senti Bio

Advanced gene and cell therapies developer

Signadoribiosignadoribio.com

Telomere Txtelomere-tx.com in

Telomere Therapeutics is a gene therapy company developing treatments that repair telomeres to address organ fibrosis and telomere-dysfunction syndromes.

BiotechHealthtechLongevity

Telumtherapeuticstelumtherapeutics.com in 𝕏

Telum Therapeutics is a drug discovery biotechnology company that uses synthetic biology and AI to engineer phage lytic enzymes (enzybiotics) as alternatives to traditional antibiotics.

AI & Machine LearningBiotechHealthtechNoáin, ES

Co-investorsAMR Action Fund

Versantisversantis.ch

Exits · 2

IPOs and acquisitions across the tracked portfolio

Alnylam PharmaceuticalsNASDAQ: ALNYBioCryst PharmaceuticalsNASDAQ: BCRX

Portfolio news

latest coverage across their companies

BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com

ProQR · investing.com · Aug 20, 2026

Frequently asked questions

How many investments has Invivo Capital Partners made?: Invivo Capital Partners has 27 tracked investments.
What stage does Invivo Capital Partners invest at?: Invivo Capital Partners invests at the Pre-Seed, Seed, Series A stages.
What is Invivo Capital Partners's typical check size?: Invivo Capital Partners typically writes checks of $2.2M – $4.3M.
What sectors does Invivo Capital Partners focus on?: Invivo Capital Partners focuses on AI & Machine Learning, Biotech, Deep Tech, Healthtech, Medical Devices.
Where is Invivo Capital Partners located?: Invivo Capital Partners is headquartered in Barcelona, ES.
Who does Invivo Capital Partners co-invest with?: Invivo Capital Partners most often shares deals with AdBio partners, Criteria Bio Ventures, Kurma Partners, among 27 tracked co-investors.

Images

Similar investors

Kleiner Perkins

Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.

$500K – $15M

Snatched Ventures

Snatched Ventures is a San Francisco-based early-stage venture capital firm backing DeepTech startups focused on sustainable innovation and operational transformation. It is led by a two-GP team combining corporate development and institutional investment management experience.

Rockies Venture Adviser, Llc

Rockies Venture Fund is a platform for early-stage venture capital funds that supports innovative startups, drawing on the deal flow and network of a national community of investors.

$100K – $500K

Sv Tech Ventures, Inc.

SV Tech Ventures is a Palo Alto-based venture capital firm investing in early-stage, high-tech startups, offering hands-on support with strategy, product, fundraising, and hiring across its funds.

Altitude Ventures Management, Llc

Altitude Life Science Ventures invests in early-stage life science companies operating in markets with strong demand and growth potential, backing high-quality teams to build durable businesses.